Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Revolutionary new treatment regimens for multidrug-resistant tuberculosis.

McHugh TD, Honeyborne I, Lipman M, Zumla A.

Lancet Infect Dis. 2019 Mar;19(3):233-234. doi: 10.1016/S1473-3099(19)30060-X. No abstract available.

PMID:
30833051
2.

World Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme Series.

Petersen E, Rao M, Ippolito G, Gualano G, Chakaya J, Ntoumi F, Moore D, Allen R, Gaskell K, Öhd JN, Hergens MP, Krishnamoorthy S, Ugarte-Gil C, Kirwan DE, Honeyborne I, McHugh TD, Köser CU, Kranzer K, Tiberi S, Migliori GB, Mao Q, Yang Y, Oliveira SP, Cardoso RF, Detjen A, Marais B, de Gijsel D, von Reyn CF, Goscé L, Abubakar I, Maeurer M, Zumla A.

Int J Infect Dis. 2019 Mar;80S:S1-S5. doi: 10.1016/j.ijid.2019.02.024. Epub 2019 Feb 23. No abstract available.

3.

The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world?

Honeyborne I, Lipman M, Zumla A, McHugh TD.

Int J Infect Dis. 2019 Mar;80S:S23-S28. doi: 10.1016/j.ijid.2019.02.006. Epub 2019 Feb 15. No abstract available.

4.

Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era.

Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, Blumberg L, Asogun D, Mukonka V, Lule SA, Bates M, Honeyborne I, Mfinanga S, Mwaba P, Dar O, Vairo F, Mukhtar M, Kock R, McHugh TD, Ippolito G, Zumla A.

Int J Infect Dis. 2019 Jan;78:78-84. doi: 10.1016/j.ijid.2018.11.008. Epub 2018 Nov 16. Review.

5.

Pediatric tuberculosis-human immunodeficiency virus co-infection in the United Kingdom highlights the need for better therapy monitoring tools: a case report.

Evangelopoulos D, Whittaker E, Honeyborne I, McHugh TD, Klein N, Shingadia D.

J Med Case Rep. 2017 Feb 26;11(1):52. doi: 10.1186/s13256-017-1222-6.

6.

The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis.

Devonshire AS, O'Sullivan DM, Honeyborne I, Jones G, Karczmarczyk M, Pavšič J, Gutteridge A, Milavec M, Mendoza P, Schimmel H, Van Heuverswyn F, Gorton R, Cirillo DM, Borroni E, Harris K, Barnard M, Heydenrych A, Ndusilo N, Wallis CL, Pillay K, Barry T, Reddington K, Richter E, Mozioğlu E, Akyürek S, Yalçınkaya B, Akgoz M, Žel J, Foy CA, McHugh TD, Huggett JF.

BMC Infect Dis. 2016 Aug 3;16:366. doi: 10.1186/s12879-016-1696-7.

7.

Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings.

Sabiiti W, Mtafya B, Kuchaka D, Azam K, Viegas S, Mdolo A, Farmer EC, Khonga M, Evangelopoulos D, Honeyborne I, Rachow A, Heinrich N, Ntinginya NE, Bhatt N, Davies GR, Jani IV, McHugh TD, Kibiki G, Hoelscher M, Gillespie SH; PANBIOME (Pan-African Biomarker Expansion Programme) consortium.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1004-9. doi: 10.5588/ijtld.15.0951.

PMID:
27393531
8.

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.

Honeyborne I, McHugh TD, Kuittinen I, Cichonska A, Evangelopoulos D, Ronacher K, van Helden PD, Gillespie SH, Fernandez-Reyes D, Walzl G, Rousu J, Butcher PD, Waddell SJ.

BMC Med. 2016 Apr 7;14:68. doi: 10.1186/s12916-016-0609-3.

9.

Airway bacteria and respiratory symptoms are common in ambulatory HIV-positive UK adults.

Nimmo C, Capocci S, Honeyborne I, Brown J, Sewell J, Thurston S, Johnson M, McHugh TD, Lipman M.

Eur Respir J. 2015 Oct;46(4):1208-11. doi: 10.1183/13993003.00361-2015. Epub 2015 Jun 25. No abstract available.

10.

Effective anti-tuberculosis therapy correlates with plasma small RNA.

Honeyborne I, Lipman MC, Eckold C, Evangelopoulos D, Gillespie SH, Pym A, McHugh TD.

Eur Respir J. 2015 Jun;45(6):1741-4. doi: 10.1183/09031936.00221214. Epub 2015 Mar 5. No abstract available.

11.

Highly reproducible absolute quantification of Mycobacterium tuberculosis complex by digital PCR.

Devonshire AS, Honeyborne I, Gutteridge A, Whale AS, Nixon G, Wilson P, Jones G, McHugh TD, Foy CA, Huggett JF.

Anal Chem. 2015 Apr 7;87(7):3706-13. doi: 10.1021/ac5041617. Epub 2015 Mar 10.

PMID:
25646934
12.

Standardization of Nucleic Acid Tests for Clinical Measurements of Bacteria and Viruses.

Pavšič J, Devonshire AS, Parkes H, Schimmel H, Foy CA, Karczmarczyk M, Gutiérrez-Aguirre I, Honeyborne I, Huggett JF, McHugh TD, Milavec M, Zeichhardt H, Žel J.

J Clin Microbiol. 2015 Jul;53(7):2008-14. doi: 10.1128/JCM.02136-14. Epub 2014 Nov 12. Review.

13.

The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.

Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics.

J Clin Microbiol. 2014 Aug;52(8):3064-7. doi: 10.1128/JCM.01128-14. Epub 2014 May 28.

14.

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment.

Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, Walzl G, Gillespie SH.

J Clin Microbiol. 2011 Nov;49(11):3905-11. doi: 10.1128/JCM.00547-11. Epub 2011 Sep 7.

15.

HLA-Cw*03-restricted CD8+ T-cell responses targeting the HIV-1 gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation.

Honeyborne I, Codoñer FM, Leslie A, Tudor-Williams G, Luzzi G, Ndung'u T, Walker BD, Goulder PJ, Prado JG.

J Virol. 2010 Nov;84(21):11279-88. doi: 10.1128/JVI.01144-10. Epub 2010 Aug 25.

16.

Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein.

Prado JG, Honeyborne I, Brierley I, Puertas MC, Martinez-Picado J, Goulder PJ.

J Virol. 2009 Jan;83(2):1018-25. doi: 10.1128/JVI.01882-08. Epub 2008 Oct 22.

17.

Central role of reverting mutations in HLA associations with human immunodeficiency virus set point.

Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, Rolland M, Honeyborne I, Carlson J, Kadie C, Brander C, Bishop K, Mlotshwa N, Mullins JI, Coovadia H, Ndung'u T, Walker BD, Heckerman D, Goulder PJ.

J Virol. 2008 Sep;82(17):8548-59. doi: 10.1128/JVI.00580-08. Epub 2008 Jul 2.

18.

Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure.

Ngumbela KC, Day CL, Mncube Z, Nair K, Ramduth D, Thobakgale C, Moodley E, Reddy S, de Pierres C, Mkhwanazi N, Bishop K, van der Stok M, Ismail N, Honeyborne I, Crawford H, Kavanagh DG, Rousseau C, Nickle D, Mullins J, Heckerman D, Korber B, Coovadia H, Kiepiela P, Goulder PJ, Walker BD.

AIDS Res Hum Retroviruses. 2008 Jan;24(1):72-82. doi: 10.1089/aid.2007.0124.

PMID:
18275350
19.

Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection.

Crawford H, Prado JG, Leslie A, Hué S, Honeyborne I, Reddy S, van der Stok M, Mncube Z, Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepiela P, Walker BD, Goulder PJ.

J Virol. 2007 Aug;81(15):8346-51. Epub 2007 May 16.

20.

Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes.

Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, Payne R, Reddy S, Bishop K, Moodley E, Nair K, van der Stok M, McCarthy N, Rousseau CM, Addo M, Mullins JI, Brander C, Kiepiela P, Walker BD, Goulder PJ.

J Virol. 2007 Apr;81(7):3667-72. Epub 2007 Jan 24.

21.

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.

Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P.

Nat Med. 2007 Jan;13(1):46-53. Epub 2006 Dec 17.

PMID:
17173051
22.

Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection.

Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N, Honeyborne I, Crawford H, Coovadia HM, Goulder PJ, Walker BD, Klenerman P.

J Virol. 2007 Jan;81(1):434-8. Epub 2006 Oct 18.

23.

Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype.

Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, Crawford H, Honeyborne I, Asher TE, Luzzi G, Edwards A, Rousseau CM, Mullins JI, Tudor-Williams G, Novelli V, Brander C, Douek DC, Kiepiela P, Walker BD, Goulder PJ.

J Immunol. 2006 Oct 1;177(7):4699-708. Erratum in: J Immunol. 2006 Dec 15;177(12):8878. Rosseau, Christine M [corrected to Rousseau, Christine M].

24.

Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa.

Honeyborne I, Rathod A, Buchli R, Ramduth D, Moodley E, Rathnavalu P, Chetty S, Day C, Brander C, Hildebrand W, Walker BD, Kiepiela P, Goulder PJ.

J Immunol. 2006 Apr 15;176(8):4699-705.

25.

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.

Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P.

J Virol. 2006 Apr;80(7):3617-23.

26.

Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses.

Ramduth D, Chetty P, Mngquandaniso NC, Nene N, Harlow JD, Honeyborne I, Ntumba N, Gappoo S, Henry C, Jeena P, Addo MM, Altfeld M, Brander C, Day C, Coovadia H, Kiepiela P, Goulder P, Walker B.

J Infect Dis. 2005 Nov 1;192(9):1588-96. Epub 2005 Sep 30.

PMID:
16206073
27.

Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.

Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman P, Korber B, Kiepiela P, Walker B, Goulder P.

J Exp Med. 2005 Mar 21;201(6):891-902.

28.

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ.

Nature. 2004 Dec 9;432(7018):769-75.

PMID:
15592417

Supplemental Content

Loading ...
Support Center